What's Next: Orforglipron (oral GLP-1) completing Phase 3 trials with submissions expected by year-end 2025 CEO Dave Ricks expects FDA approval by March 2026 International launches accelerating in China, Brazil, India, and Mexico The GLP-1 market is projected to exceed $100B+ by the early 2030s, and Lilly is positioned as the category leader
Consult Your Doctor: Before starting any new supplement regimen, especially if you have health concerns or conditions, consult with a healthcare professional to ensure it's safe and right for you
Things like repair signaling, hormone release, inflammation response, and metabolic regulation
NEB) digestion (Figure 1B, lower panel), and confirmed by subsequent sequencing (ACGT)
Comas-Bast O, Snchez-Prez S, Veciana-Nogus MT, Latorre-Moratalla M, Vidal-Carou MC